Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

Robert Orlowski, Thierry Facon, Shaji Kumar, Torben Plesner, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher Venner, Katja Weisel, Joseph Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent FrenzelXavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Usmani

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
TidsskriftClinical Lymphoma Myeloma and Leukemia
Vol/bind21
Udgave nummerSuppl. 1
Sider (fra-til)S424-S425
ISSN2152-2650
DOI
StatusUdgivet - 1. sep. 2021
BegivenhedThe ninth annual meeting of the Society of Hematologic Oncology - Virtuelt
Varighed: 8. sep. 202111. sep. 2021
Konferencens nummer: 9

Konference

KonferenceThe ninth annual meeting of the Society of Hematologic Oncology
Nummer9
LokationVirtuelt
Periode08/09/202111/09/2021

Citationsformater